1. Home
  2. GCTS vs IPHA Comparison

GCTS vs IPHA Comparison

Compare GCTS & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GCT Semiconductor Holding Inc.

GCTS

GCT Semiconductor Holding Inc.

HOLD

Current Price

$2.47

Market Cap

227.4M

Sector

Finance

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

HOLD

Current Price

$1.79

Market Cap

189.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GCTS
IPHA
Founded
1998
1999
Country
United States
France
Employees
126
163
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
227.4M
189.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
GCTS
IPHA
Price
$2.47
$1.79
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
4
Target Price
$3.50
$5.75
AVG Volume (30 Days)
3.3M
9.0K
Earning Date
05-12-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$1,052.30
$180.36
Revenue Next Year
$140.29
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.96
$1.18
52 Week High
$3.93
$2.63

Technical Indicators

Market Signals
Indicator
GCTS
IPHA
Relative Strength Index (RSI) 46.67 49.12
Support Level $2.35 $1.70
Resistance Level $3.21 $1.80
Average True Range (ATR) 0.30 0.09
MACD -0.05 -0.00
Stochastic Oscillator 17.96 16.63

Price Performance

Historical Comparison
GCTS
IPHA

About GCTS GCT Semiconductor Holding Inc.

GCT Semiconductor Holding Inc is a designer and supplier of 5G and 4G LTE semiconductor solutions. It enabled fast and reliable 4G LTE connectivity to numerous commercial devices such as CPEs, mobile hotspots, routers, M2M applications, and smartphones, etc. The system-on-chip solutions integrate radio frequency, baseband modem, and digital signal processing functions, therefore offering complete 4G and 5G platform solutions with small form factors, low power consumption, high performance, high reliability, and cost-effectiveness. Geographically, operates in South Korea and the United States, with maximum revenue from the USA.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: